To address this concern, we have performed a 300-fold dilution series of the computer virus sample and labeled the samples with the same antibody concentrations (Fig. stomatitis computer virus (VSV). Using a panel of monoclonal antibodies, we were able to detect the S protein on the surface of the recombinant VSV computer virus, monitor the manifestation levels, detect variations in the antigen based on S protein sequence and after computer virus inactivation, and monitor S protein stability. Collectively, circulation virometry provided important data that helped to guide preclinical development of this vaccine candidate. 1.?Introduction Circulation virometry is an emerging technique that is opening new avenues for studying viruses and extracellular vesicles [1], [2]. This technique allows for the enumeration and detailed characterization of particles using both their light-scattering characteristics and molecular markers, such as nucleic acids or specific protein antigens [3], [4]. The ability to employ specific antibodies allows these methods to address a variety of different questions, including protein maturation state [5] or conformation [6], [7], [8]. Coronavirus disease 2019 (Covid 19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) offers swiftly spread across the world and became the most severe pandemic in recent history. An unprecedented worldwide effort offers led to quick development of several highly efficacious vaccines [9] and the development of additional vaccines continues [10]. The vaccines are based on viral Spike (S) protein, which mediates binding to target cells and subsequent fusion. Coronavirus S protein is a class I fusion protein [11] arranged into homotrimers within the viral surface. The protein is expressed inside a metastable prefusion conformation [12], which is the main target of neutralizing antibodies [13], [14]. The structure of the pre-fusion trimer was determined by cryo-transmission electron microscopy [15]. S protein consists of two ITM2A practical subunits, S1 and S2. The S1 subunit contains the receptor-binding website (RBD), while the S2 subunit contains the viral fusion machinery and the membrane anchor. SARS-CoV-2, but not additional SARS-like viruses, offers developed a multi fundamental cleavage site in the S1-S2 boundary [16]. Cleavage of the multi fundamental site by furin primes the S protein for fusion and is thought to be responsible for the high infectivity of SARS-CoV-2 relative to related Coronaviruses. Human being angiotensin-converting enzyme 2 (hACE2) serves as the receptor for SARS-CoV-2 HAE [16]. Upon receptor binding, the cellular serine protease TMPRSS2 is definitely recruited to cleave S protein at a S2 cleavage site, which exposes the fusion peptide and consequently prospects to fusion [17]. Stabilization of the metastable prefusion conformation is essential for the development of S protein-based vaccines. This has mainly been HAE achieved by introducing two consecutive proline residues (2P) in the loop between the 1st heptad repeat and the central helix [15], [18]. For a successful development of a new vaccine, detailed understanding of the immunogen is essential. However, due to the difficulty of viral vaccines, achieving in-depth analytical understanding of the sample is definitely demanding and fresh methods are needed to accelerate vaccine development. In this statement, we show the application of circulation virometry to characterize a Covid 19 vaccine candidate produced from a recombinant VSV viral vector expressing SARS-CoV-2 S protein. Our data demonstrate that circulation virometry is a powerful tool for monitoring crucial attributes of viral samples throughout all phases of viral vaccine development, including antigen selection in the finding phase, process development in the pre-clinical stage, and product quality monitory in later on phases. Additionally, the relatively short time required for data acquisition makes circulation virometry amenable HAE for real-time process monitoring as a part of Process Analytical Technology (PAT) toolbox. 2.?Material and methods 2.1. Vaccine candidate preparation Replication-competent, chimeric computer virus (VSVG-SARS-CoV-2).